1551 results about "Gastric acid" patented technology

Chemical syntheses and medical uses of novel inhibitors of the gastric H⁺, K⁺-ATPase for the treatment and/or management of duodenal ulcers, heartburn, acid reflux, other conditions mediated by gastric acid secretion and/or psoriasis are described.

Pharmaceutical compositions comprising a proton pump inhibitor, one or more buffering agent and a nonsteroidal anti-inflammatory drug are described. Methods are described for treating gastric acid related disorders and treating inflammatory disorders, using pharmaceutical compositions comprising a proton pump inhibitor, a buffering agent, and a nonsteroidal anti-inflammatory drug.

A method for reducing ecologically adverse changes of the gastrointestinal micro-flora in patients under treatment with medicaments (which may also be referred to herein as the therapeutic compounds or medications) such as gastric acid reducing medicaments or antibiotics. A pharmaceutical product useful in the present method comprising a medicament and a probiotically active organism as a combined preparation presented in a commercial package unit.

The present invention is directed to, inter alia, pharmaceutical compositions comprising at least one proton pump inhibitor and at least one buffering agent. Compositions of the invention are useful in treating, inter alia, gastric acid related disorders.

A prosthesis (13) for implanting in an upper stomach to prevent gastric reflux in an esophagus comprising a tube (17) made of a biocompatible polymer that is resistant to gastric acid, the tube having an upper end and a lower end, a length, and a generally constant diameter along the entire length thereof, the upper end having means (16) for securing to the upper stomach, the lower end having at least one slit (18) to facilitate inversion of the tube during vomiting but to facilitate collapsing of the tube under pressure generated by gastric reflux.

Disclosed herein are compositions and methods for treating gastric acid disorders employing pharmaceutical compositions comprising a proton pump inhibitor (PPI) in a pharmaceutically acceptable carrier.

The sulfonamide or carboamide derivatives of the formula (I) and a pharmaceutical composition which comprise them as an active ingredient:(wherein A ring, B ring is carbocyclic ring, heterocyclic ring; Z1 is -COR1, -CH=CH-COR1 etc.; Z2 is H, alkyl etc.; Z3 is single bond, alkylene; Z4 is SO2, CO; Z5 is alkyl, phenyl, heterocyclic ring etc.; R2 is CONR8, O, S, NZ6, Z7-alkylene, alkylene etc.; R3 is H, alkyl, halogen, CF3 etc.; R4 is H, (substituted) alkyl etc.; n, t is 1-4).The compounds of the formula (I) can bind to receptors of PGE2 and show antagonistic activity against the action thereof or agonistic activity. Therefore, they are considered to be useful as medicine for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, medicine for increase of vesical capacity or medicine for uterine contraction, cathartic, suppression of gastric acid secretion, antihypertensive or diuretic agents.

A method for treating Barrett's esophagus and esophageal cancer by using non-thermal electroporation energy to ablate diseased portions of the esophagus which, in effect, prevents stomach acids and other fluids from entering the esophagus thereby alleviating continued deterioration of the esophagus and allows the columnar cells in the lining of the esophagus to assume their normal physical characteristics and functions and.

An volume filling device for treatment of obesity is placed outside the stomach wall of the patient to reduce the inner volume of the stomach, thereby affecting the patient's appetite. By providing the volume filling device outside the stomach wall, contact with stomach acids is avoided, thereby increasing the life of the device.

An implantable device for the treatment of acid reflux disease has a body including an outer surface adapted to rest against a patient's fundus wall. The device, when implanted in a patient, fills a volume in the patient's abdomen in the cardia area and above the cardia of the patient, when standing. The body prevents the cardia from moving through the diaphragm opening into the thorax, thereby preventing reflux by keeping the abdominal pressure supporting the cardia sphincter muscle. The device may be affixed to stomach tissue. The device may also be invaginated or otherwise indirectly secured in position.

A unit dosage form, such as a capsule or the like, for delivering drugs into the body in a circadian release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need at different times during the dosing period, i.e., mimicking the circadian rhythm and severity/manifestation of gastric acid secretion (and/or midnight gerd), predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.

The invention provides a lactobacillus helveticus microcapsule as well as the preparation and application thereof, pertaining to the embedding technology of lactobacillus helveticus and aiming at microencapsulating the lactobacillus helveticus so as to solve the problems of low embedding efficiency and embedding yield in single-layer or double-layer embedment. The technical proposal adopted by the invention is that isolated soy protein, microporous starch and sodium alginate are respectively taken as the first, the second and the third layers of wall materials for microencapsulation; the three-layer embedment is carried out to the lactobacillus helveticus for the first time, wherein, in the process of preparing bacterial suspension, an orthogonal optimization protective agent is adopted to improve the livability after freeze drying. The microcapsule of the invention has strong heat resistance and acid resistance, solves the inactivation problem caused by gastric acid, digestive enzyme and antibiotic, etc. to active bacillus, is capable of releasing when reaching large intestine, and balances intestinal flora. The reusability of fermented milk is good. The lactobacillus helveticus used by the invention enriches the variety of probiotic bacteria microcapsule and is a good dietary supplement.

The invention specifically relates to a bifidobacterium microcapsule and a preparing method thereof. The bifidobacterium is obligatorily anaerobic and very sensitive to oxygen, PH, temperature, humidity, and other adverse external environment, thereby being very hard to remain activity during production, storage and transport; besides, if taken orally in a form of dry bifidobacterium powder, the bifidobacterium cannot tolerate low-pH value gastric acid, bile salt, and other environments, so a purpose that massive survived bifidobacteria arrive at an intestinal tract and colonise on the intestinal mucosa is hard to be guaranteed. The preparing method disclosed by the invention comprises the following steps of: adding freeze-dried bifidobacterium powder into a sodium alginate solution and then mixing in soybean oil, emulsifying the mixed solution and standing; centrifugally collecting micro-capsules; and drying the micro-capsules by using a vacuum freeze-drying technology. The bifidobacterium microcapsule disclosed by the invention has the advantages of gastric acid resistance, bile salt resistance and entericsolubility, high survival rate of bifidobacterium, simple preparation method, strong practicality, convenience for industrial production, and excellent storage stability and solves the problem of short storage period of probiotics preparations.

The invention provides bacillus subtilis K018 which is strong in stress resistance, excellent in probiotics function and safe and reliable, a biological feed additive containing the bacillus subtilis K018 and use thereof. The bacillus subtilis K018 provided by the invention can resist artificial gastric acid, cholate, artificial intestinal juice and high temperature, has stronger inhibiting effects to pathogenic staphylococcus aureus, escherichia coli, salmonella enteritidis and the like in the intestinal tract, is stronger in amylase and cellulase generating capacity, and can degrade starch and cellulose.

Pharmaceutical compositions comprising a proton pump inhibitor, one or more buffering agent and a sleep aid are described. Methods are described for treating gastric acid related disorders and inducing sleep, using pharmaceutical compositions comprising a proton pump inhibitor, a buffering agent, and a sleep aid.

(1) Prostaglandin (PG) E2 antagonist or agonist containing carbocyclic sulfonamides represented by the compound of the formula (I): cyclodextrin clathrates thereof, non-toxic salts thereof as active ingredient, (2) carbocyclic sulfonamides represented by the compound of the formula (II): cyclodextrin clathrates thereof, non-toxic salts thereof, (3) process for the preparation of the compound represented by the compound of the formula (II) described hereinbefore, (4) PGE2 antagonist or agonist containing the compound represented by the compound of the formula (II) as active ingredient. The compounds represented by the compounds of the formula (I) and (II) can be adapted to medicines which possess an inhibitory effect of uterine contraction, an analgetic action, an inhibitory effect of digestive peristalsis, a sleep-inducing effect as PGE2 antagonists, and an uterine contractile activity, a promoting effect of digestive peristalsis, a suppressive effect of gastric acid secretion, a hypotensive activity as PGE2 agonists, because they bind onto PGE2 receptor and have an activity of antagonist or agonist against the action thereof.

The invention belongs to the technical field of feed micro-ecology and relates to a composite micro-ecological preparation as well as a premixed material and an application of the preparation in a feed additive. The preparation contains Lactobacillus acidophilus powder and any two, three or four bacterium powders selected from Bacillus licheniformis, Bcillus pumilus, enteroccus and Bcillus subtilis; the preparation has high live bacteria content and low moisture content, has stress tolerance properties such as gastric acid resistance, cholate resistance, high temperature resistance, common antibiotics tolerance and the like and has the probiotic functions of producing acid and enzyme, inhibiting pathogenic bacteria and the like. By using the composite micro-ecological preparation of the invention, the utilization rate of the feed can be improved, the yields of meat, eggs, milk and the like are increased, the growth of animals is promoted, the immunity and disease-resistant capability of an animal organism are improved, and partial preparation can be used for replacing antibiotics, thereby changing the quality of an animal product.

The invention relates to an animal Bifidobacterium and a use method thereof. The animal Bifidobacterium is the Bifidobactrium amimalis Subsp Lactis B174, the CGMCC No. is 4182, the conservation date is September 16, 2010 and the conservation unit is the China General Microbiological Culture Collection Center. The Bifidobactrium amimalis Subsp Lactis B174 can colonize in human body and resist the gastric acid and cholate of human body. Meanwhile, the strain has better inhibitory action on Escherichia coli and can survive for 30 days at the room temperature. The strain and other lactic acid bacteria have better synergic action for growth; the strain has better combination effect with lactic acid bacteria; the product has better flavor, can be used to prepare fermented yoghurt, animal feed additives and antibacterial solution and can be widely used in the fields of other foods and biological products.